Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.48 |
| ▸ | AMY2A | P04746 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | MGAM | O43451 | 2/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21883716 | 1.00 | AMY1A (0.48) | AMY1AAMY2AGAAMGAMSI | |
| SCHEMBL8915660 | 1.00 | AMY1A (0.48) | AMY1AAMY2AGAAMGAMSI | |
| SCHEMBL18323930 | 0.90 | AMY1A (0.48) | AMY1AAMY2AGAAPTGS1ALDH1A1 | |
| SCHEMBL16904113 | 0.90 | AMY1A (0.48) | AMY1AAMY2AGAAPTGS1ALDH1A1 | |
| SCHEMBL17773084 | 0.90 | AMY1A (0.48) | AMY1AAMY2AGAAPTGS1ALDH1A1 | |
| SCHEMBL17773086 | 0.90 | AMY1A (0.48) | AMY1AAMY2AGAAPTGS1ALDH1A1 | |
| SCHEMBL17773089 | 0.90 | AMY1A (0.48) | AMY1AAMY2AGAAPTGS1ALDH1A1 | |
| SCHEMBL17773088 | 0.90 | AMY1A (0.48) | AMY1AAMY2AGAAPTGS1ALDH1A1 | |
| SCHEMBL11147760 | 0.89 | AMY1A (0.47) | AMY1AAMY2AGAAMGAMSI | |
| SCHEMBL11147765 | 0.89 | AMY1A (0.47) | AMY1AAMY2AGAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610539-B2 | Cardiac glycoside analogs and their use in methods for inhibition of viral infection | THE JOHN HOPKINS UNIVERSITY (US) | 2020-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10610539-B2 | Cardiac glycoside analogs and their use in methods for inhibition of viral infection | ATP1A3, ATP1A2, ATP1B3 | AMY1A 1903/4885AMY2A 2699/4885GAA 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.